291 related articles for article (PubMed ID: 1656045)
1. Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity.
Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Marsden BJ; Wilkes BC
J Med Chem; 1991 Oct; 34(10):3125-32. PubMed ID: 1656045
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and activity profiles of novel cyclic opioid peptide monomers and dimers.
Schiller PW; Nguyen TM; Lemieux C; Maziak LA
J Med Chem; 1985 Dec; 28(12):1766-71. PubMed ID: 2999401
[TBL] [Abstract][Full Text] [Related]
3. Cyclic beta-casomorphin analogues with mixed mu agonist/delta antagonist properties: synthesis, pharmacological characterization, and conformational aspects.
Schmidt R; Vogel D; Mrestani-Klaus C; Brandt W; Neubert K; Chung NN; Lemieux C; Schiller PW
J Med Chem; 1994 Apr; 37(8):1136-44. PubMed ID: 8164255
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of cyclic opioid peptide analogues containing a phenylalanine residue in the 3-position.
Schiller PW; Nguyen TM; Maziak LA; Wilkes BC; Lemieux C
J Med Chem; 1987 Nov; 30(11):2094-9. PubMed ID: 2822930
[TBL] [Abstract][Full Text] [Related]
5. Conformationally restricted deltorphin analogues.
Schiller PW; Weltrowska G; Nguyen TM; Wilkes BC; Chung NN; Lemieux C
J Med Chem; 1992 Oct; 35(21):3956-61. PubMed ID: 1331451
[TBL] [Abstract][Full Text] [Related]
6. Development of a model for the delta opioid receptor pharmacophore. 2. Conformationally restricted Phe3 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13).
Mosberg HI; Omnaas JR; Lomize A; Heyl DL; Nordan I; Mousigian C; Davis P; Porreca F
J Med Chem; 1994 Dec; 37(25):4384-91. PubMed ID: 7996550
[TBL] [Abstract][Full Text] [Related]
7. Conformation-activity relationships of cyclic dermorphin analogues.
Wilkes BC; Schiller PW
Biopolymers; 1990 Jan; 29(1):89-95. PubMed ID: 2158362
[TBL] [Abstract][Full Text] [Related]
8. Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists.
Schiller PW; Nguyen TM; Weltrowska G; Wilkes BC; Marsden BJ; Lemieux C; Chung NN
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11871-5. PubMed ID: 1334552
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics simulations of opioid peptide analogs containing multiple conformational restrictions.
Wilkes BC; Schiller PW
Int J Pept Protein Res; 1992; 40(3-4):249-54. PubMed ID: 1478782
[TBL] [Abstract][Full Text] [Related]
10. A novel cyclic opioid peptide analog showing high preference for mu-receptors.
Schiller PW; Nguyen TM; Maziak L; Lemieux C
Biochem Biophys Res Commun; 1985 Mar; 127(2):558-64. PubMed ID: 2983726
[TBL] [Abstract][Full Text] [Related]
11. Selective opioid dipeptides.
Temussi PA; Salvadori S; Amodeo P; Bianchi C; Guerrini R; Tomatis R; Lazarus LH; Picone D; Tancredi T
Biochem Biophys Res Commun; 1994 Feb; 198(3):933-9. PubMed ID: 8117299
[TBL] [Abstract][Full Text] [Related]
12. Theoretical conformational analysis of the opioid delta antagonist H-Tyr-Tic-Phe-OH and the mu agonist H-Tyr-D-Tic-Phe-NH2.
Wilkes BC; Schiller PW
Biopolymers; 1994 Sep; 34(9):1213-9. PubMed ID: 7948733
[TBL] [Abstract][Full Text] [Related]
13. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
[TBL] [Abstract][Full Text] [Related]
14. Substitution of aromatic and nonaromatic amino acids for the Phe3 residue in the delta-selective opioid peptide deltorphin I: effects on binding affinity and selectivity.
Heyl DL; Schmitter SJ; Bouzit H; Johnson TW; Hepp AM; Kurtz KR; Mousigian C
Int J Pept Protein Res; 1994 Nov; 44(5):420-6. PubMed ID: 7896499
[TBL] [Abstract][Full Text] [Related]
15. Effect of aromatic amino acid substitutions in the 3-position of cyclic beta-casomorphin analogues on mu-opioid agonist/delta-opioid antagonist properties.
Schmidt R; Wilkes BC; Chung NN; Lemieux C; Schiller PW
Int J Pept Protein Res; 1996 Nov; 48(5):411-9. PubMed ID: 8956074
[TBL] [Abstract][Full Text] [Related]
16. Pseudoproline-containing analogues of morphiceptin and endomorphin-2: evidence for a cis Tyr-Pro amide bond in the bioactive conformation.
Keller M; Boissard C; Patiny L; Chung NN; Lemieux C; Mutter M; Schiller PW
J Med Chem; 2001 Nov; 44(23):3896-903. PubMed ID: 11689075
[TBL] [Abstract][Full Text] [Related]
17. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
Vig BS; Zheng MQ; Murray TF; Aldrich JV
J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
[TBL] [Abstract][Full Text] [Related]
18. Conformational features responsible for the binding of cyclic analogues of enkephalin to opioid receptors. III. Probable binding conformations of mu-agonists with phenylalanine in position 3.
Shenderovich MD; Nikiforovich GV; Golbraikh AA
Int J Pept Protein Res; 1991 Apr; 37(4):241-51. PubMed ID: 1654306
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of cyclic beta-casomorphin-5 analogues.
Schmidt R; Neubert K; Barth A; Liebmann C; Schnittler M; Chung NN; Schiller PW
Peptides; 1991; 12(6):1175-80. PubMed ID: 1667685
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors.
Kazmierski W; Wire WS; Lui GK; Knapp RJ; Shook JE; Burks TF; Yamamura HI; Hruby VJ
J Med Chem; 1988 Nov; 31(11):2170-7. PubMed ID: 2903246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
